Melatonin

Melatonin, the active ingredient in this product, is a melatonin receptor agonist presented as an oral dosage form for oral use. It assists the body’s natural sleep‑wake cycle and is employed to improve sleep onset and quality in adults with insomnia, jet lag, or circadian rhythm sleep disorders.

GNH USA supplies melatonin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring product quality through stringent manufacturing and distribution standards. The company adheres to EU GMP guidelines and provides reliable logistics for global markets.

Melatonin acts on melatonin receptors to help normalize the sleep‑wake cycle in various sleep‑related conditions.

Insomnia: improves sleep onset and reduces nighttime awakenings in adults. Jet lag: facilitates adjustment of the circadian clock after rapid time‑zone travel. Circadian rhythm sleep disorder: stabilizes abnormal sleep timing in shift‑work or delayed sleep phase syndrome.

Melatonin may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Drowsiness or daytime sleepiness - Headache - Dizziness - Nausea

Serious or Rare Side Effects: - Allergic skin reactions (rash, itching, swelling) - Severe hypersensitivity (anaphylaxis) - Mood changes (depression, irritability)

When considering melatonin therapy, several safety measures and warnings should be observed.

Consult healthcare provider: verify suitability for individual health conditions. Avoid use with driving: potential residual drowsiness may impair performance. Pregnancy and breastfeeding: discuss risks with a physician before use. Concurrent medications: review possible interactions with other sleep‑affecting agents. Store at ambient temperature below 25°C: keep in original container, protect from moisture and light.

Melatonin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): may increase bleeding risk. - Immunosuppressants (e.g., cyclosporine): potential reduction in drug effectiveness. - Central nervous system depressants (e.g., benzodiazepines): additive sedative effect.

Moderate Interactions (Monitor Closely): - CYP1A2 inhibitors (e.g., fluvoxamine): may raise melatonin plasma levels. - Oral contraceptives: may enhance melatonin’s effect on hormone balance. - Antihypertensives: possible additive blood pressure lowering.